Assessment of the sedative effects of dexmedetomidine and propofol treatment in patients undergoing mechanical ventilation in the ICU and relationship between treatment and occurrence of ventilator‑associated pneumonia and detection of pathogenic bacteria

  • Authors:
    • Hongjie Dou
    • Fangbao Hu
    • Wen Wang
    • Lin Ling
    • Deqiang Wang
    • Fenlian Liu
  • View Affiliations

  • Published online on: April 29, 2020     https://doi.org/10.3892/etm.2020.8699
  • Pages: 599-606
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to investigate the sedative effects of dexmedetomidine combined with propofol in patients undergoing mechanical ventilation in the intensive care unit (ICU), and to reveal the risk factors of ventilator‑associated pneumonia (VAP). A retrospective analysis of 322 patients who had been subject to mechanical ventilation in the ICU ward was performed. Subjects were divided into two groups: A group treated with dexmedetomidine and propofol (combined group) and a group treated with dexmedetomidine alone (monotherapy group). Clinical data, sedative effects, the number of VAP patients and the distribution of VAP pathogens were assessed. Multivariate analysis and receiver operating characteristic (ROC) curves were used to predict VAP. Significant differences in the sedative effects between the two groups were observed (P<0.001). The incidence of VAP was significantly higher in the monotherapy group compared with the combined group (P<0.05). Multivariate logistic regression analysis demonstrated that age, acute physiology chronic health evaluation score, consciousness, invasive operations, recovery time, extubation time and sedation regimen were independent risk factors for VAP in the ICU during mechanical ventilation. ROC curves indicated that the areas under the curve for age, acute physiology chronic health score, consciousness, invasive operations, recovery time, extubation time and sedation regimen were 0.934, 0.870, 0.632, 0.677, 0.865, 0.950 and 0.603, respectively. In summary, dexmedetomidine combined with propofol can shorten the recovery and extubation times of mechanical ventilation patients in the ICU. Different sedation schemes are also independent risk factors for VAP during mechanical ventilation in the ICU.
View Figures
View References

Related Articles

Journal Cover

July-2020
Volume 20 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Dou H, Hu F, Wang W, Ling L, Wang D and Liu F: Assessment of the sedative effects of dexmedetomidine and propofol treatment in patients undergoing mechanical ventilation in the ICU and relationship between treatment and occurrence of ventilator‑associated pneumonia and detection of pathogenic bacteria. Exp Ther Med 20: 599-606, 2020
APA
Dou, H., Hu, F., Wang, W., Ling, L., Wang, D., & Liu, F. (2020). Assessment of the sedative effects of dexmedetomidine and propofol treatment in patients undergoing mechanical ventilation in the ICU and relationship between treatment and occurrence of ventilator‑associated pneumonia and detection of pathogenic bacteria. Experimental and Therapeutic Medicine, 20, 599-606. https://doi.org/10.3892/etm.2020.8699
MLA
Dou, H., Hu, F., Wang, W., Ling, L., Wang, D., Liu, F."Assessment of the sedative effects of dexmedetomidine and propofol treatment in patients undergoing mechanical ventilation in the ICU and relationship between treatment and occurrence of ventilator‑associated pneumonia and detection of pathogenic bacteria". Experimental and Therapeutic Medicine 20.1 (2020): 599-606.
Chicago
Dou, H., Hu, F., Wang, W., Ling, L., Wang, D., Liu, F."Assessment of the sedative effects of dexmedetomidine and propofol treatment in patients undergoing mechanical ventilation in the ICU and relationship between treatment and occurrence of ventilator‑associated pneumonia and detection of pathogenic bacteria". Experimental and Therapeutic Medicine 20, no. 1 (2020): 599-606. https://doi.org/10.3892/etm.2020.8699